Arrowhead Research Corporation - ARWR STOCK NEWS

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has finalized an exclusive license agreement with GlaxoSmithKline (LSE/NYSE: GSK) for ARO-HSD, a therapeutic for nonalcoholic steatohepatitis (NASH). Arrowhead will receive a $120 million upfront payment and could earn up to $1.1 billion in additional milestone payments and royalties. The agreement allows GSK to develop ARO-HSD globally, except in Greater China, where Arrowhead retains rights. The transaction is expected to close in Q1 2022, pending customary conditions.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a collaboration with Janssen Pharmaceuticals on the investigational compound JNJ-75220795, currently in a Phase 1 clinical study. This siRNA therapeutic targets the reduction of PNPLA3 expression in the liver, aimed at treating non-alcoholic steatohepatitis (NASH). The collaboration began in October 2018 and leverages Arrowhead's TRIM platform, demonstrating the potential to address significant liver disease by targeting genetic factors associated with fat accumulation.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Janssen Pharmaceuticals presented clinical data from the REEF-1 Phase 2b study at The Liver Meeting. The study assessed combination therapies, including JNJ-3989 and JNJ-6379, for chronic hepatitis B infection. Key findings highlighted a dose-dependent response, with 19.1% of patients meeting NA stopping criteria at week 48. The JNJ-3989 200 mg cohort showed a 2.6 log10 reduction in HBsAg at week 48. Overall, treatments were well-tolerated, and additional combination studies are underway.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented additional Phase 1/2 clinical data for ARO-APOC3 at the American Heart Association's Scientific Sessions 2021. The investigational RNA interference therapy targets apolipoprotein C-III and aims to treat hypertriglyceridemia. Key findings include a 98% reduction in APOC3 among familial chylomicronemia patients and well-tolerated administration across various doses. The therapy demonstrated significant decreases in triglycerides and increases in HDL-C, suggesting it as a promising option for patients with severe hypertriglyceridemia.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented interim clinical data from its AROHSD1001 study at The Liver Meeting, showcasing ARO-HSD's potential for treating liver diseases like NASH. Key findings included a dose-dependent reduction in HSD17B13 mRNA, with over 90% reduction at 200 mg in all patients. Additionally, liver fat reductions were noted in 9 out of 18 patients. ARO-HSD was well-tolerated, with no serious adverse events linked to the drug. This investigational therapy aims to leverage RNA interference to combat liver diseases effectively.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced interim clinical data from the ongoing AROAAT2002 study of ARO-AAT, a treatment for alpha-1 antitrypsin deficiency. Key outcomes include a 72-100% reduction in liver Z-AAT protein and notable improvements in liver fibrosis in 6 out of 14 patients. Additionally, the treatment successfully reduced histological globule burden and normalized liver health biomarkers. No significant adverse events were reported, indicating a favorable safety profile. Arrowhead is collaborating with Takeda, receiving $300 million upfront, with potential milestone earnings of $740 million.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a conference call and webcast on November 22, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal year ending September 30, 2021. Investors can access the live audio via the company's website at ir.arrowheadpharma.com. A replay will be available for 90 days post-call. Arrowhead focuses on developing RNAi-based therapeutics to treat intractable diseases through gene silencing technology.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is scheduled to participate in several key events from November 12-30, 2021. Highlights include presentations during the Liver Meeting (AASLD) featuring findings on ARO-AAT and ARO-HSD therapies, as well as results from the Phase 2B REEF-1 Study for chronic hepatitis B. Additionally, CEO Chris Anzalone will engage in fireside chats at both the Jefferies London Healthcare Conference and the Piper Sandler Healthcare Conference. These events underline Arrowhead’s commitment to advancing RNA interference therapeutics.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application for clearance to initiate a Phase 1/2a clinical trial of ARO-C3, an investigational RNA interference therapeutic for complement-mediated diseases. The trial aims to evaluate safety and pharmacokinetics in healthy volunteers and patients with specific renal conditions. Arrowhead will host a KOL webinar on October 26, 2021, to elaborate on ARO-C3's development and its potential to treat unmet medical needs in renal and hematology diseases, including IgA nephropathy and paroxysmal nocturnal hemoglobinuria.